Han H L, Lyu Q P
Department of Otorhinolaryngology Head and Neck Surgery, China-Japan Friendship Hospital, Beijing 100029, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2022 Nov 7;57(11):1323-1327. doi: 10.3760/cma.j.cn115330-20220216-00069.
To evaluate the clinical effect of vonoprazan fumarate on laryngopharyngeal reflux disease (LPRD). The clinical data of 89 patients from June 2020 to January 2022, including 45 males and 44 females, aged 18-77 (45.54±13.53) years old, were retrospectively analyzed. All the patients were diagnosed as suspected LPRD according to reflux symptom index (RSI) and reflux finding score (RFS). Patients of the Vonoprazan Fumarate group were prescribed Vonoprazan Fumarate orally (20 mg, qd) for 8 weeks.Patients of the Esomeprazole group were prescribed Esomeprazole orally (20 mg, bid) for 8 weeks. RSI and RFS of all the patients before and after treatment were compared. SPSS 18.0 was used for statistics analysis. Before treatment, gender, age, RSI and RFS of the two groups had no obvious differences. After treatment, RSI and RFS in both groups were alleviated significantly. In the vonorazan fumarate group, the RSI before treatment was 12.62±7.18, and after treatment was 4.74±3.87(=6.91, <0.001), the RFS was 10.78±2.29 before treatment and 8.24±2.45 after treatment (=7.06, <0.001). While in the esomeprazole group, the RSI was 13.27±6.95 before treatment and 6.02±4.28 after treatment (=7.50, <0.001), the RFS was 10.59±3.14 before treatment and 8.14±3.30 after treatment (=5.41, <0.001). There was no significant difference in the effective rate between the two groups (86.7% in the vonoprazan fumarate group and 77.3% in the esomeprazole group, =1.443, =0.486). Vonoprazan fumarate could effectively alleviate the symptoms and signs of LPRD patients. The effect of vonoprazan fumarate on LPRD is not inferior to Esomeprazole. It can be used as a supplement to PPI.
评估富马酸沃克索拉唑治疗喉咽反流病（LPRD）的临床效果。回顾性分析2020年6月至2022年1月89例患者的临床资料，其中男性45例，女性44例，年龄18 - 77岁（45.54±13.53）岁。所有患者均根据反流症状指数（RSI）和反流发现评分（RFS）诊断为疑似LPRD。富马酸沃克索拉唑组患者口服富马酸沃克索拉唑（20 mg，每日1次），疗程8周。埃索美拉唑组患者口服埃索美拉唑（20 mg，每日2次），疗程8周。比较所有患者治疗前后的RSI和RFS。采用SPSS 18.0进行统计学分析。治疗前，两组患者的性别、年龄、RSI和RFS无明显差异。治疗后，两组患者的RSI和RFS均明显改善。富马酸沃克索拉唑组治疗前RSI为12.62±7.18，治疗后为4.74±3.87（t = 6.91，P < 0.001），治疗前RFS为10.78±2.29，治疗后为8.24±2.45（t = 7.06，P < 0.001）。而埃索美拉唑组治疗前RSI为13.27±6.95，治疗后为6.02±4.28（t = 7.50，P < 0.001），治疗前RFS为10.59±3.14，治疗后为8.14±3.30（t = 5.41，P < 0.001）。两组有效率无显著差异（富马酸沃克索拉唑组为86.7%，埃索美拉唑组为77.3%，z = 1.443，P = 0.486）。富马酸沃克索拉唑可有效缓解LPRD患者的症状和体征。富马酸沃克索拉唑治疗LPRD的效果不劣于埃索美拉唑。它可作为质子泵抑制剂（PPI）的补充药物。
